Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 6Esophageal Squamous Cell Carcinoma 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Gastric Adenocarcinoma 2Cholangiocarcinoma 2Breast Neoplasms 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Adenocarcinoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Radioactive Iodine-refractory Differentiated Thyroid Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroblastoma 1Malignant Neoplasms of Digestive Organs 1Liver Neoplasms 1Gestational Trophoblastic Disease 1Gastrointestinal Stromal Tumors 1Fludzoparib" and Anti-angiogenic 1Colonic Neoplasms 1Cirrhosis, Familial, with Pulmonary Hypertension 1Advanced Primary Liver Cancer 1Advanced Biliary Tract Carcinoma 1Adebrelimab 1

Interventions

Imatinib Mesylate 12Sunitinib 10ripretinib 5regorafenib 4Blood Specimen Collection 3envafolimab 2Specimen Handling 2Paclitaxel 2Magnetic Resonance Spectroscopy 2IDRX-42 2Biopsy 2trastuzumab deruxtecan 1spartalizumab 1ribociclib 1pemigatinib 1palbociclib 1olverembatinib 1nilotinib 1guadecitabine 1binimetinib 1avelumab 1avapritinib 1atezolizumab 1apatinib 1Temozolomide 1TAS-116 1Surgical Instruments 1Sorafenib 1Rogaratinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Stromal Tumors × apatinib × 1 year × Clear all
NCT05905887 2026-04-07

Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor

Asan Medical Center

Phase 2 Recruiting
48 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡